Valuation: Orexo AB

Market Cap 213M 21.47M 19.14M 17.75M 16.13M 30.3M 2.04B 30.76M 83.63M 1.06B 80.56M 78.86M 3.43B P/E 2024
-2.97x
P/E 2025 1.63x
Enterprise Value -208M -20.99M -18.71M -17.35M -15.77M -29.62M -1.99B -30.07M -81.75M -1.04B -78.75M -77.09M -3.35B EV / Sales 2024
1.62x
EV / Sales 2025 23.8x
Free-Float
78.37%
Yield 2024 *
-
Yield 2025 -
1 day-3.03%
1 week-12.46%
Current month-58.14%
1 month-55.00%
3 months-62.79%
6 months-72.57%
Current year-80.86%
1 week 5.74
Extreme 5.74
6.39
1 month 5.74
Extreme 5.74
14.8
Current year 5.74
Extreme 5.74
36
1 year 5.74
Extreme 5.74
40.15
3 years 5.74
Extreme 5.74
43.4
5 years 5.74
Extreme 5.74
43.4
10 years 5.74
Extreme 5.74
87.9
Manager TitleAgeSince
Chief Executive Officer 54 04/02/2013
Director of Finance/CFO 59 31/08/2022
Chief Tech/Sci/R&D Officer - 30/09/2024
Director TitleAgeSince
Director/Board Member 64 31/12/2001
Director/Board Member 70 10/04/2019
Director/Board Member 62 31/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
04/09/25 Buy

Chief Executive Officer

6 0.0000%
04/09/25 Free

Chief Executive Officer

1,393 0.0040%
03/09/25 Free 149 0.0004% -
Change 5-day change 1-year change 3-year change Capi.($)
-3.03%-12.46%-85.29%-62.74% 22.16M
-1.33%+5.18%+54.50%+104.26% 1,120B
-0.69%-2.93%+31.35%+66.17% 616B
-0.96%+2.25%+23.13%+89.36% 504B
+0.24%+6.23%+33.98%+52.38% 367B
-1.59%-1.35%+69.39%+40.83% 360B
-0.40%+4.28%+19.17%+42.51% 288B
-0.37%+3.35%-1.26%+16.85% 258B
-1.75%+2.43%+42.21%+49.85% 234B
-2.00%+1.26%+24.64%+92.13% 194B
Average -1.19%+2.01%+21.18%+49.16% 394.09B
Weighted average by Cap. -0.99%+3.52%+37.89%+71.72%

Financials

2024 2025
Net sales 590M 59.52M 53.06M 49.19M 44.72M 83.99M 5.65B 85.27M 232M 2.95B 223M 219M 9.5B 26M 2.62M 2.34M 2.17M 1.97M 3.7M 249M 3.76M 10.22M 130M 9.84M 9.63M 419M
Net income -203M -20.48M -18.26M -16.92M -15.39M -28.9M -1.94B -29.34M -79.76M -1.01B -76.84M -75.21M -3.27B 639M 64.49M 57.5M 53.3M 48.46M 91.01M 6.12B 92.39M 251M 3.2B 242M 237M 10.3B
Net Debt 353M 35.58M 31.72M 29.41M 26.73M 50.21M 3.38B 50.97M 139M 1.76B 133M 131M 5.68B -421M -42.46M -37.86M -35.09M -31.9M -59.92M -4.03B -60.83M -165M -2.1B -159M -156M -6.78B
Projected Income Statement - Annual - Orexo AB
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
19/10/26 SEK 5.760 -3.03% 40,711
16/10/26 SEK 5.940 +0.68% 22,125
15/10/26 SEK 5.900 -2.64% 134,382
14/10/26 SEK 6.060 -0.66% 116,628
13/10/26 SEK 6.100 -1.45% 106,610
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Orexo AB

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Orexo AB